Who We Are
What We Do
How We Do It
Where We Do It
Value, Access, and Pricing
A new economic era is dawning, and understanding how value can best support price and access will be essential to the success of future and current brands.
From new modes of administration to new mechanisms of action, specialty therapeutic landscapes are crowding with new dimensions of competition. Understanding local market perceptions and behaviours are just the beginning to developing a sound commercial strategy with the expertise of CBPartners’ team.
As market and payer realities evolve, it will be essential to adapt to meet new stakeholder needs, as well as to understand the value of that adaptation.
Government Policy Advisory
The world’s landscape is quickly evolving due to both innovation and government policy. Ensuring that these policies match political and commercial goals is possible through the expertise of CBPartners’ team.
Strategic Thinking: The Global Drug Launch Pricing Dilemma
29 January 2020
American Society for Hematology (ASH) 2019 Annual Meeting: Our Recommended CAR T Cell Therapy Innovation Talks
22 November 2019
The Cancer Drugs Fund: Paving the way for earlier and more sustainable access to promising new drugs
19 November 2019
Developing an early stage biopharmaceutical asset in Europe: Navigating treacherous waters
29 October 2019
Deal with it: FTC regulation of innovative biopharmaceutical escalates during record-breaking M&A streak
9 October 2019
Fecal Transplant Treatment: The Messy Pathway to Reimbursement
26 September 2019
ICER and Pharmaceutical Manufacturers: Allies or Adversaries?
11 September 2019
View All Blog Posts
ISPOR International: Times That Try Souls
07 July 2017
Cyrus A. Chowdhury
Sandeep Duttagupta, PhD
ISPOR BOSTON: Pharmaceutical Strategic Pricing: An Analysis of Global Cross-SKU Pricing Approaches
ISPOR BOSTON: The Effectiveness of the FDA Priority Review Voucher for Neglected Tropical Diseases and Rare Pediatric Diseases
ISPOR BOSTON: Risk-Sharing Agreements (RSA) in Emerging Markets: Is it a Wake-Up Call or is it Innovation Too Late?
ISPOR BOSTON: How the Purchase and Use of a FDA Priority Review Voucher Affects Product Uptake and Value Conversion
Forecasting Failure: Learning from the Accuracy of Hindsight
ISPOR Asia 2016: Taming Enthusiasm
View All White Papers